--- title: "Health Canada Approves Merck's Keytruda With Enfortumab Vedotin For Bladder Cancer" type: "News" locale: "en" url: "https://longbridge.com/en/news/294992831.md" description: "Health Canada has approved Merck's Keytruda in combination with enfortumab vedotin for adults with muscle-invasive bladder cancer ineligible for cisplatin-based chemotherapy. This approval, based on the Phase 3 KEYNOTE-905 trial conducted with Pfizer and Astellas, allows Keytruda to be used as neoadjuvant treatment followed by surgery and adjuvant therapy. The combination demonstrated significant improvements in event-free survival, overall survival, and pathological complete response rates compared to surgery alone." datetime: "2026-08-05T16:25:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294992831.md) - [en](https://longbridge.com/en/news/294992831.md) - [zh-HK](https://longbridge.com/zh-HK/news/294992831.md) generator: "portal-rs" --- # Health Canada Approves Merck's Keytruda With Enfortumab Vedotin For Bladder Cancer Add as your preferred news source on Google Add Now Merck & Co., Inc. (MRK), known as MSD outside the United States and Canada, said on Wednesday that Health Canada approved its cancer drug Keytruda in combination with enfortumab vedotin for certain adults with muscle-invasive bladder cancer. The approval covers patients who are ineligible for cisplatin-containing chemotherapy. Keytruda will be used as neoadjuvant treatment, followed by radical cystectomy, and then continued as adjuvant treatment after surgery. Keytruda, or pembrolizumab, is Merck's anti-PD-1 therapy. Enfortumab vedotin is an antibody-drug conjugate. The approval was based on data from the Phase 3 KEYNOTE-905 trial, also known as EV-303. The trial was conducted with Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMF). It showed a statistically significant improvement in event-free survival and overall survival for patients treated with the combination versus radical cystectomy and pelvic lymph node dissection alone. It also showed a statistically significant difference in pathological complete response rate. "Muscle-invasive bladder cancer can have a significant impact on patients and their families, particularly for those who are not candidates for cisplatin-based chemotherapy," said Michelle Colero, Executive Director at Bladder Cancer Canada. On the NYSE, shares of Merck & Co are currently gaining 1.22 percent, changing hands at $129.56. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [ALPMY.US](https://longbridge.com/en/quote/ALPMY.US.md) - [4503.JP](https://longbridge.com/en/quote/4503.JP.md) ## Related News & Research - [Crew Capital Management Ltd Acquires 7,742 Shares of Merck & Co., Inc. $MRK](https://longbridge.com/en/news/296582210.md) - [Vise Technologies Inc. Purchases 96,548 Shares of Pfizer Inc. $PFE](https://longbridge.com/en/news/296698057.md) - [Munich Reinsurance Co Stock Corp in Munich Grows Stake in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/296202779.md) - [Narwhal Capital Management Reduces Holdings in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/296329835.md) - [Pfizer (PFE) Reaches Deal Covering About 5,000 Federal Lawsuit Claims](https://longbridge.com/en/news/296430772.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**